3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia
3
Neoplasms
2
Melanoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Philadelphia Chromosome
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Hypereosinophilic Syndrome
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Graft vs Host Disease
1
Digestive System Neoplasms
1
Desmoid Tumors
1
Dermatofibrosarcoma
1
Congenital Bone Marrow Failure Syndromes
1
Chordoma
1
Carcinoma, Adenoid Cystic
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Imatinib Mesylate
×
1 year
×
Clear all
No trials found.